Showing results (1-10 of 9) with videos related to
Sort By:
Pageof 1
Eksperimental'Naia I Klinicheskaia Farmakologiia|August 4, 2011
[Possibilities of using interferon-induction therapy during latent HBV infection]V V Stel'makhTerapevticheskii Arkhiv|July 2, 2013
[Metabolic correction of dyslipidemia in patients with nonalcoholic fatty liver disease as a new therapy policy]V V Stel'makh, V K KozlovTerapevticheskii Arkhiv|April 27, 2011
[Metabolic correctors based on succinic acid as pathogenic therapy in chronic virus hepatitis]V V Stel'makh, V G Radchenko, V K KozlovEksperimental'Naia I Klinicheskaia Farmakologiia|August 8, 2018
EXPERIMENTAL ASSESSMENT OF THE SPECIFIC EFFICIENCY OF NEW METABOLIC DRUG RUNIKHOL ON MODELS OF NON-ALCOHOLIC FATTY LIVER DISEASEV V Stel'makh, A P Trashkov, A L Kovalenko, et al.Klinicheskaia Meditsina|September 25, 2012
[Pathogenetic therapy of metabolic syndrome at the stage of visceral lesions]V V Stel'makh, V K Kozlov, V G Radchenko, et al.Georgian Medical News|July 19, 2013
[Meglumine acridonacetate in combined antiviral treatment of HBeAg-positive chronic hepatitis B]V V Stel'makh, S V Okovityĭ, M G Romantsov, et al.Antibiotiki I Khimioterapiia = Antibiotics and Chemoterapy [Sic]|April 18, 2014
[Comparative efficacy of etiotropic therapy of patients with HBeAg-positive chronic hepatitis B (by the data of the international comparative placebo-controlled study)]V V Stel'makh, M G Romantsov, T V Sologub, et al.Klinicheskaia Meditsina|October 6, 2010
[Reamberin for pathogenetic therapy of acute and chronic viral diseases of the liver]T V Sologub, M G Romantsov, A A Shul'diakov, et al.Terapevticheskii Arkhiv|October 26, 2022
[The results of phase III multicenter open randomized controlled study REM-Chol-III-16 in patients with intrahepatic cholestasis syndrome caused by chronic diffuse liver diseases]V V Stel'makh, A L Kovalenko, V B Popova, et al.Pageof 1